Dr Reddy's Laboratories

DRL trims workforce costs by 25% amid Revlimid-linked margin strain

There are 21,757 permanent employees on company rolls as on March 31, 2024; cost optimisation to offset margin pressure due to declining Revlimid sales

A year of narrow gains: Just 5 secure keys to trillion-plus vault in FY25

Meanwhile, eight companies dropped off the list: among them were IndusInd Bank, Indian Overseas Bank, Canara Bank, Dr Reddy's Laboratories, Adani Total Gas, and Zydus Lifesciences

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Bio-Thera, Dr. Reddy's partner for biosimilar expansion in Southeast Asia

With this partnership, they aim to enhance access to affordable treatments for patients suffering from autoimmune diseases

Bajaj Finance, TaMo, Maruti: Largecap buy, sell stock ideas post Q3 results

Here's a technical outlook on 5 largecap stocks post Q3 results. Charts hint towards a positive bias for Bajaj Finance and Bajaj Auto; whereas a likely fall for Maruti, Tata Motors and Dr. Reddy's.

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Dr. Reddy's pops 4% after Nuvama upgrades to 'Buy'; arm sells US mfg unit

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy' from 'Reduce'

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab

Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%

Analysts expect Dr Reddy's Labs to report a single digit fall in profits with a double digit revenue growth

Dr Reddy's completes acquisition of Haleon's global NRT portfolio

DRL's Swiss subsidiary completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group company

Dr Reddy's gets USFDA's inspection report for Srikakulam-based API plant

Dr Reddy's Laboratories on Friday said it has received the establishment inspection report (EIR) from the US health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The US Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is close, the Hyderabad-based drug maker said in a statement. As per USFDA, VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. On June 7 this year, Dr Reddy's had stated that the US health regulator has issued Form 483 with four observations after inspecting its Srikakulam-based facility. Shares of the company on Friday ended 0.42 per cent down at Rs 6,669.75 apiece on the BSE.

Dr Reddy's, Lupin recall products in US due to manufacturing issues: USFDA

Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories Inc, a subsidiary of Hyderabad-based drug firm, is recalling Ibuprofen tablets in multiple strengths, the US health regulator said in its latest enforcement report. Ibuprofen tablets are indicated for pain relief and fever. New Jersey-based Dr Reddy's Laboratories Inc. is recalling 1,03,298 bottles (800 mg); 31,802 bottles (600 mg); and 14,940 bottles (400 mg) of Ibuprofen tablets in the US market, USFDA said. The company is recalling the affected lot due to "Failed impurities/degradation specifications," it added. "Results for unknown impurity were 0.13 per cent and 0.11 per cent, respectively, exceeding the 0.10 per cent specification limit," USFDA noted. The company initiated the Class II nationwide recall on August 6 this year. USFDA stated that Lupin is recalling 4,554 bottles of Cefixime for Oral Suspen

Dr Reddy's Labs Q1 Preview: Market share loss in products to drag profits

Indian drugmaker, Dr Reddy's Laboratories is all set to deliver its financial performance for the first quarter of financial year 2024-25 (Q1FY25) on Saturday, July 27, 2024

Dr Reddy's Lab pushes the pedal to touch 1.5 billion patients by FY30

The company also announced that it will work together with the United States Food and Drug Administration (USFDA) to launch the biosimilar rituximab in the US

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition

In India, DRL has an OTC portfolio in the hydration, cough-cold-allergy, and skin care categories

Dr. Reddy's to acquire Haleon's nicotine replacement biz for 500 mn pounds

The acquisition includes Nicotinell, a global leader in the NRT category, and its local market-leading brand names Nicabate, Habitrol, and Thrive

Stocks to Watch, June 14: Voda Idea, Dr Reddy's, Suzlon, Signature Global

Stocks to Watch on Friday, June 14: Vodafone Idea (Vi) has decided to offer a Rs 2,458 crore stake to long-term vendors Nokia and Ericsson in a bid to partially clear outstanding dues

Buzzing stocks, June 10: Order boost for KEC, RVNL; USFDA action on DRL

Stocks to Watch on Monday, June 10: RVNL's joint venture with KRDCL has emerged as the lowest bidder for a project worth Rs 156 crore

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024